<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04557540</url>
  </required_header>
  <id_info>
    <org_study_id>I 684220</org_study_id>
    <secondary_id>NCI-2020-06640</secondary_id>
    <secondary_id>I 684220</secondary_id>
    <nct_id>NCT04557540</nct_id>
  </id_info>
  <brief_title>Weight Loss Interventions for Black Adults of Faith</brief_title>
  <official_title>Comparison of Intermittent Fasting With Continuous Caloric Reduction in Black Adults of Faith</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Roswell Park Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Roswell Park Cancer Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial compares the effect of intermittent fasting versus continuous caloric reduction&#xD;
      for the reduction of body weight in Black adults of faith. Intermittent fasting and&#xD;
      continuous caloric reduction interventions may help Black adults of faith lose weight,&#xD;
      improve their health, and help reduce cancer risk.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:&#xD;
&#xD;
      I. Partner with the First Ladies of Western New York (FLOW) to engage 10 community&#xD;
      stakeholders from Black churches in the Roswell Park Catchment area in a four-stage process&#xD;
      involving information gathering, discussion groups, and mock intervention delivery to create&#xD;
      Fasting WORD for Black adults of faith.&#xD;
&#xD;
      II. Implement and determine the initial comparative effectiveness of Fasting WORD with The&#xD;
      WORD to reduce body weight, and biomarkers of obesity, inflammation, insulin, and insulin&#xD;
      resistance.&#xD;
&#xD;
      SECONDARY OBJECTIVES:&#xD;
&#xD;
      I. Examine the interventions' effects on diet and physical activity. II. Examine&#xD;
      participants' adherence and satisfaction with both interventions.&#xD;
&#xD;
      OUTLINE: Participants are randomized to 1 of 2 arms.&#xD;
&#xD;
      ARM I: Participants receive the Fasting WORD intermittent fasting weight loss intervention&#xD;
      consisting of 16 small-group lessons over 1.5 hours each once a week (QW) for 2 months and&#xD;
      then once every 2 weeks (Q2W) for 4 months.&#xD;
&#xD;
      ARM II: Participants receive The WORD continuous energy restriction (CER) weight loss&#xD;
      intervention consisting of 16 small-group lessons over 1.5 hours each QW for 2 months and&#xD;
      then Q2W for 4 months.&#xD;
&#xD;
      After completion of study, participants are followed up for 30 days.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 25, 2020</start_date>
  <completion_date type="Anticipated">September 15, 2023</completion_date>
  <primary_completion_date type="Anticipated">September 15, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in body weight</measure>
    <time_frame>Up to 6 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in body composition</measure>
    <time_frame>up to 6 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in height</measure>
    <time_frame>up to 6 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in heart rate</measure>
    <time_frame>Up to 6 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in blood pressure</measure>
    <time_frame>AT 6 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in waist circumference</measure>
    <time_frame>Up to t 6 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in hip circumference</measure>
    <time_frame>Up to 6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Dietary intake</measure>
    <time_frame>Up to 6 months</time_frame>
    <description>Dietary intake will be assessed by the interview-administered Nutrition Data System for Research (NDSR).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Obesity-related biomarker analysis</measure>
    <time_frame>Up to 6 months</time_frame>
    <description>Will measure biomarkers related to , including C-peptide, as a marker of insulin secretion Will assay for 6 adipokines including leptin, adiponectin, adipsin, lipocalin-2/NGAL, resistin, and PAI-1 (total) as markers of adiposity and adiposity-related metabolic dysfunction, including insulin resistance, and CRP as a well-characterized and validated marker for systemic inflammation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>glucose metabolism</measure>
    <time_frame>UP to 6 months</time_frame>
    <description>Change from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>changes in Adipokine levels</measure>
    <time_frame>Up to 6 months</time_frame>
    <description>blood concentration measure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>C-Peptide level</measure>
    <time_frame>Up to 6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Obesity-Related Malignant Neoplasm</condition>
  <arm_group>
    <arm_group_label>Arm I (Fasting WORD)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants receive the Fasting WORD intermittent fasting weight loss intervention consisting of 16 small-group lessons over 1.5 hours each QW for 2 months and then Q2W for 4 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm II (The WORD)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants receive The WORD CER weight loss intervention consisting of 16 small-group lessons over 1.5 hours each QW for 2 months and then Q2W for 4 months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Lifestyle Therapy</intervention_name>
    <description>Receive The WORD lifestyle CER weight loss intervention</description>
    <arm_group_label>Arm II (The WORD)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Quality-of-Life Assessment</intervention_name>
    <description>Ancillary studies</description>
    <arm_group_label>Arm I (Fasting WORD)</arm_group_label>
    <arm_group_label>Arm II (The WORD)</arm_group_label>
    <other_name>Quality of Life Assessment</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Questionnaire Administration</intervention_name>
    <description>Ancillary studies</description>
    <arm_group_label>Arm I (Fasting WORD)</arm_group_label>
    <arm_group_label>Arm II (The WORD)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Short-Term Fasting</intervention_name>
    <description>Receive Fasting WORD intermittent fasting weight loss intervention</description>
    <arm_group_label>Arm I (Fasting WORD)</arm_group_label>
    <other_name>Intermittent Fasting</other_name>
    <other_name>Short-term Intermittent Fasting</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  African American/Black&#xD;
&#xD;
          -  Body mass index (BMI) &gt; 25 kg/m^2&#xD;
&#xD;
          -  Associated with a participating church through membership or participation in a church&#xD;
             activity&#xD;
&#xD;
          -  Cleared by a Primary Care Provider (PCP-Doctor) to be a part of the study&#xD;
&#xD;
          -  Not currently on weight loss medications&#xD;
&#xD;
          -  Not pregnant or lactating&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Adults unable to consent&#xD;
&#xD;
          -  Adults unable to complete study measures in English&#xD;
&#xD;
          -  Individuals who are not yet adults (infants, children, teenagers)&#xD;
&#xD;
          -  Individuals who are pregnant or lactating&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Karen Yeary</last_name>
    <role>Principal Investigator</role>
    <affiliation>Roswell Park Cancer Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Roswell Park Cancer Institute</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14263</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karen Yeary</last_name>
      <phone>716-845-1300</phone>
      <phone_ext>6231</phone_ext>
      <email>Karen.Yeary@roswellpark.org</email>
    </contact>
    <investigator>
      <last_name>Karen Yeary</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>September 9, 2020</study_first_submitted>
  <study_first_submitted_qc>September 15, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 21, 2020</study_first_posted>
  <last_update_submitted>September 3, 2021</last_update_submitted>
  <last_update_submitted_qc>September 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

